Cargando…

Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes

Currently, there is no ideal noninvasive method to quantify the progressive loss of pancreatic β-cell mass (BCM) that occurs in type 1 diabetes. Magnetic resonance imaging has detected gross differences in BCM between healthy and diabetic mice using the contrast agent manganese, which labels functio...

Descripción completa

Detalles Bibliográficos
Autores principales: Antkowiak, Patrick F., Stevens, Brian K., Nunemaker, Craig S., McDuffie, Marcia, Epstein, Frederick H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526033/
https://www.ncbi.nlm.nih.gov/pubmed/22933107
http://dx.doi.org/10.2337/db12-0153
_version_ 1782253493621358592
author Antkowiak, Patrick F.
Stevens, Brian K.
Nunemaker, Craig S.
McDuffie, Marcia
Epstein, Frederick H.
author_facet Antkowiak, Patrick F.
Stevens, Brian K.
Nunemaker, Craig S.
McDuffie, Marcia
Epstein, Frederick H.
author_sort Antkowiak, Patrick F.
collection PubMed
description Currently, there is no ideal noninvasive method to quantify the progressive loss of pancreatic β-cell mass (BCM) that occurs in type 1 diabetes. Magnetic resonance imaging has detected gross differences in BCM between healthy and diabetic mice using the contrast agent manganese, which labels functional β-cells and increases the water proton relaxation rate (R1), but its ability to measure gradations in BCM during disease progression is unknown. Our objective was to test the hypothesis that measurements of the manganese-enhanced pancreatic R1 could detect decreasing BCM in a mouse model of type 1 diabetes. We used cyclophosphamide-accelerated BDC2.5 T-cell receptor transgenic nonobese diabetic mice, which experience development of type 1 diabetes during a 7-day time period after cyclophosphamide injection, whereas transgene-negative mice do not. We measured the manganese-enhanced pancreatic R1 before cyclophosphamide injection (day 0) and on days 3, 4, 5, and 7 afterward. Pancreatic R1 remained constant in transgene-negative mice and decreased stepwise day-to-day in transgene-positive mice, mirroring their loss of BCM, confirmed by pancreatic insulin measurements and histology. Changes in R1 in transgene-positive mice occurred before elevations in blood glucose, a clinical indicator of diabetes, suggesting potential for early noninvasive detection of changes in functional BCM.
format Online
Article
Text
id pubmed-3526033
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-35260332014-01-01 Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes Antkowiak, Patrick F. Stevens, Brian K. Nunemaker, Craig S. McDuffie, Marcia Epstein, Frederick H. Diabetes Technological Advances Currently, there is no ideal noninvasive method to quantify the progressive loss of pancreatic β-cell mass (BCM) that occurs in type 1 diabetes. Magnetic resonance imaging has detected gross differences in BCM between healthy and diabetic mice using the contrast agent manganese, which labels functional β-cells and increases the water proton relaxation rate (R1), but its ability to measure gradations in BCM during disease progression is unknown. Our objective was to test the hypothesis that measurements of the manganese-enhanced pancreatic R1 could detect decreasing BCM in a mouse model of type 1 diabetes. We used cyclophosphamide-accelerated BDC2.5 T-cell receptor transgenic nonobese diabetic mice, which experience development of type 1 diabetes during a 7-day time period after cyclophosphamide injection, whereas transgene-negative mice do not. We measured the manganese-enhanced pancreatic R1 before cyclophosphamide injection (day 0) and on days 3, 4, 5, and 7 afterward. Pancreatic R1 remained constant in transgene-negative mice and decreased stepwise day-to-day in transgene-positive mice, mirroring their loss of BCM, confirmed by pancreatic insulin measurements and histology. Changes in R1 in transgene-positive mice occurred before elevations in blood glucose, a clinical indicator of diabetes, suggesting potential for early noninvasive detection of changes in functional BCM. American Diabetes Association 2013-01 2012-12-13 /pmc/articles/PMC3526033/ /pubmed/22933107 http://dx.doi.org/10.2337/db12-0153 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Technological Advances
Antkowiak, Patrick F.
Stevens, Brian K.
Nunemaker, Craig S.
McDuffie, Marcia
Epstein, Frederick H.
Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title_full Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title_fullStr Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title_full_unstemmed Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title_short Manganese-Enhanced Magnetic Resonance Imaging Detects Declining Pancreatic β-Cell Mass in a Cyclophosphamide-Accelerated Mouse Model of Type 1 Diabetes
title_sort manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes
topic Technological Advances
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526033/
https://www.ncbi.nlm.nih.gov/pubmed/22933107
http://dx.doi.org/10.2337/db12-0153
work_keys_str_mv AT antkowiakpatrickf manganeseenhancedmagneticresonanceimagingdetectsdecliningpancreaticbcellmassinacyclophosphamideacceleratedmousemodeloftype1diabetes
AT stevensbriank manganeseenhancedmagneticresonanceimagingdetectsdecliningpancreaticbcellmassinacyclophosphamideacceleratedmousemodeloftype1diabetes
AT nunemakercraigs manganeseenhancedmagneticresonanceimagingdetectsdecliningpancreaticbcellmassinacyclophosphamideacceleratedmousemodeloftype1diabetes
AT mcduffiemarcia manganeseenhancedmagneticresonanceimagingdetectsdecliningpancreaticbcellmassinacyclophosphamideacceleratedmousemodeloftype1diabetes
AT epsteinfrederickh manganeseenhancedmagneticresonanceimagingdetectsdecliningpancreaticbcellmassinacyclophosphamideacceleratedmousemodeloftype1diabetes